EQ
|Equillium Inc
NASDAQ
USD 0.39
+0.02|+5.46%
Current Price
USD 0.39
Change
+USD 0.02 (5.46%)
P/E Ratio
Dividend Yield
Market Cap
14.29M
Volume
46,588
Open
USD 0.36
Previous Close
USD 0.37
52-Week High
USD 1.53
52-Week Low
USD 0.34
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Bruce D. Steel C.F.A.
Employees:35
Headquarters:La Jolla, USA
Website:www.equilliumbio.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions